Scarlet Therapeutics is developing a proprietary platform that generates novel red blood cell-based therapeutics (tRBCs) to treat a wide range of diseases. Its technologies are underpinned by learnings from decades of research including the groundbreaking RESTORE clinical study run by NHS Blood and Transplant and the University of Bristol, investigating transfusion of lab-grown blood into patients. By generating tRBCs with high levels of therapeutic proteins from cell lines rather than from donated stem cells, Scarlet Therapeutics aims to address significant efficacy and manufacturing issues faced in the field.

NuNano is advancing the field of atomic force microscopy with high-precision probes for nanometer-scale imaging. Its proprietary microfabrication processes produce reliable, high-quality probes with market-leading dimensional tolerances. It also provides dedicated support to its customers, from probe selection to storage, for a seamless user experience.

GenomeKey is transforming how healthcare clinicians diagnose and treat infections like sepsis to improve patient outcomes. Using cutting-edge machine learning and DNA sequencing, the company is developing a next-generation diagnostic device to identify bacterial genomes and determine their antimicrobial susceptibility directly from patient blood in just a few hours, rather than days. This enables clinicians to prescribe the right antibiotics for patients with much more efficiency and accuracy, reducing costs, minimising unnecessary antibiotic use and ultimately saving millions of lives from the world’s leading cause of death.

EnsiliTech is improving the shelf-life and global accessibility of vaccines and other biological therapeutics by combatting cold chain transport and storage issues. Its novel ensilication technology, designed for both existing and new biopharmaceutical formulations, encases thermally unstable biomolecules within silica nanoshells to prevent environmental degradation. This eliminates the need for cold chain requirements that are expensive, prone to failure and generate significant carbon dioxide emissions.

Carbometrics is striving to improve diabetes patient care by enhancing technology for continuous glucose monitoring. The team aims to pave the way for a new class of highly-accurate sensors with its groundbreaking synthetic molecule that is both chemically stable and able to bind to glucose in the blood. This follows on from the work of exited startup Ziylo Ltd, which was Science Creates’ very first resident and acquired by Novo Nordisk in 2018.

Anaphite is decarbonising battery production by accelerating the electric vehicle (EV) industry’s shift to dry battery electrode coating. Its technology platform solves the challenges of dry mixing and manufactures film-forming dry powders called Dry Coating Precursor (DCP®). This process enables cell manufacturers to reduce their energy use by up to 30% and create better, more sustainable batteries at lower cost.